vs
Guardant Health, Inc.（GH）与ROYAL GOLD INC（RGLD）财务数据对比。点击上方公司名可切换其他公司
ROYAL GOLD INC的季度营收约是Guardant Health, Inc.的1.3倍（$375.3M vs $281.3M），ROYAL GOLD INC净利率更高（24.9% vs -45.7%，领先70.6%），ROYAL GOLD INC同比增速更快（85.3% vs 39.4%），过去两年ROYAL GOLD INC的营收复合增速更高（58.8% vs 29.2%）
Guardant Health, Inc.是总部位于美国加利福尼亚州帕洛阿尔托的生物技术企业，由Helmy Eltoukhy与AmirAli Talasaz联合创立，目前二人共同出任公司首席执行官，统筹公司战略规划与日常运营管理工作。
Royal Gold Inc.是全球领先的贵金属流权与特许权经营企业，收购并管理多元化的矿业项目流权、净熔炼收益特许权及相关权益，资产覆盖黄金、白银、铜等品类，业务遍及多地区，无需直接承担采矿运营风险。
GH vs RGLD — 直观对比
营收规模更大
RGLD
是对方的1.3倍
$281.3M
营收增速更快
RGLD
高出45.9%
39.4%
净利率更高
RGLD
高出70.6%
-45.7%
两年增速更快
RGLD
近两年复合增速
29.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $281.3M | $375.3M |
| 净利润 | $-128.5M | $93.6M |
| 毛利率 | 64.6% | 64.6% |
| 营业利润率 | -43.0% | 56.2% |
| 净利率 | -45.7% | 24.9% |
| 营收同比 | 39.4% | 85.3% |
| 净利润同比 | -15.8% | -12.8% |
| 每股收益（稀释后） | $-1.01 | $1.04 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GHRGLD
| Q4 25 | $281.3M | $375.3M | ||
| Q3 25 | $265.2M | $252.1M | ||
| Q2 25 | $232.1M | $209.6M | ||
| Q1 25 | $203.5M | $193.4M | ||
| Q4 24 | $201.8M | $202.6M | ||
| Q3 24 | $191.5M | $193.8M | ||
| Q2 24 | $177.2M | $174.1M | ||
| Q1 24 | $168.5M | $148.9M |
净利润GHRGLD
| Q4 25 | $-128.5M | $93.6M | ||
| Q3 25 | $-92.7M | $126.8M | ||
| Q2 25 | $-99.9M | $132.3M | ||
| Q1 25 | $-95.2M | $113.5M | ||
| Q4 24 | $-111.0M | $107.4M | ||
| Q3 24 | $-107.8M | $96.2M | ||
| Q2 24 | $-102.6M | $81.2M | ||
| Q1 24 | $-115.0M | $47.2M |
毛利率GHRGLD
| Q4 25 | 64.6% | 64.6% | ||
| Q3 25 | 64.7% | 73.6% | ||
| Q2 25 | 65.0% | 72.6% | ||
| Q1 25 | 63.3% | 69.4% | ||
| Q4 24 | 61.6% | 70.3% | ||
| Q3 24 | 61.1% | 66.6% | ||
| Q2 24 | 59.1% | 64.7% | ||
| Q1 24 | 61.2% | 58.4% |
营业利润率GHRGLD
| Q4 25 | -43.0% | 56.2% | ||
| Q3 25 | -37.3% | 64.4% | ||
| Q2 25 | -45.9% | 67.7% | ||
| Q1 25 | -54.6% | 63.6% | ||
| Q4 24 | -62.4% | 65.9% | ||
| Q3 24 | -61.3% | 61.3% | ||
| Q2 24 | -56.8% | 58.6% | ||
| Q1 24 | -59.2% | 50.7% |
净利率GHRGLD
| Q4 25 | -45.7% | 24.9% | ||
| Q3 25 | -35.0% | 50.3% | ||
| Q2 25 | -43.0% | 63.1% | ||
| Q1 25 | -46.8% | 58.7% | ||
| Q4 24 | -55.0% | 53.0% | ||
| Q3 24 | -56.3% | 49.7% | ||
| Q2 24 | -57.9% | 46.6% | ||
| Q1 24 | -68.2% | 31.7% |
每股收益（稀释后）GHRGLD
| Q4 25 | $-1.01 | $1.04 | ||
| Q3 25 | $-0.74 | $1.92 | ||
| Q2 25 | $-0.80 | $2.01 | ||
| Q1 25 | $-0.77 | $1.72 | ||
| Q4 24 | $-0.90 | $1.63 | ||
| Q3 24 | $-0.88 | $1.46 | ||
| Q2 24 | $-0.84 | $1.23 | ||
| Q1 24 | $-0.94 | $0.72 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $378.2M | $233.7M |
| 总债务越低越好 | $1.5B | — |
| 股东权益账面价值 | $-99.3M | $7.2B |
| 总资产 | $2.0B | $9.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GHRGLD
| Q4 25 | $378.2M | $233.7M | ||
| Q3 25 | $580.0M | $172.8M | ||
| Q2 25 | $629.1M | $248.2M | ||
| Q1 25 | $698.6M | $240.8M | ||
| Q4 24 | $525.5M | $195.5M | ||
| Q3 24 | $585.0M | $127.9M | ||
| Q2 24 | $933.7M | $74.2M | ||
| Q1 24 | $1.0B | $137.9M |
总债务GHRGLD
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $50.0M | ||
| Q1 24 | — | — |
股东权益GHRGLD
| Q4 25 | $-99.3M | $7.2B | ||
| Q3 25 | $-354.5M | $3.4B | ||
| Q2 25 | $-305.5M | $3.3B | ||
| Q1 25 | $-250.8M | $3.2B | ||
| Q4 24 | $-139.6M | $3.1B | ||
| Q3 24 | $-60.1M | $3.0B | ||
| Q2 24 | $-1.6M | $3.0B | ||
| Q1 24 | $68.3M | $2.9B |
总资产GHRGLD
| Q4 25 | $2.0B | $9.5B | ||
| Q3 25 | $1.3B | $4.5B | ||
| Q2 25 | $1.3B | $3.6B | ||
| Q1 25 | $1.3B | $3.5B | ||
| Q4 24 | $1.5B | $3.4B | ||
| Q3 24 | $1.5B | $3.3B | ||
| Q2 24 | $1.6B | $3.3B | ||
| Q1 24 | $1.7B | $3.3B |
负债/权益比GHRGLD
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.02× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-26.4M | $241.7M |
| 自由现金流经营现金流 - 资本支出 | $-54.2M | — |
| 自由现金流率自由现金流/营收 | -19.3% | — |
| 资本支出强度资本支出/营收 | 9.9% | — |
| 现金转化率经营现金流/净利润 | — | 2.58× |
| 过去12个月自由现金流最近4个季度 | $-233.1M | — |
8季度趋势，按日历期对齐
经营现金流GHRGLD
| Q4 25 | $-26.4M | $241.7M | ||
| Q3 25 | $-35.4M | $174.0M | ||
| Q2 25 | $-60.3M | $152.8M | ||
| Q1 25 | $-62.7M | $136.4M | ||
| Q4 24 | $-64.5M | $141.1M | ||
| Q3 24 | $-51.1M | $136.7M | ||
| Q2 24 | $-94.0M | $113.5M | ||
| Q1 24 | $-30.3M | $138.3M |
自由现金流GHRGLD
| Q4 25 | $-54.2M | — | ||
| Q3 25 | $-45.8M | — | ||
| Q2 25 | $-65.9M | — | ||
| Q1 25 | $-67.1M | — | ||
| Q4 24 | $-83.4M | — | ||
| Q3 24 | $-55.3M | — | ||
| Q2 24 | $-99.1M | — | ||
| Q1 24 | $-37.2M | — |
自由现金流率GHRGLD
| Q4 25 | -19.3% | — | ||
| Q3 25 | -17.3% | — | ||
| Q2 25 | -28.4% | — | ||
| Q1 25 | -33.0% | — | ||
| Q4 24 | -41.3% | — | ||
| Q3 24 | -28.9% | — | ||
| Q2 24 | -55.9% | — | ||
| Q1 24 | -22.1% | — |
资本支出强度GHRGLD
| Q4 25 | 9.9% | — | ||
| Q3 25 | 3.9% | — | ||
| Q2 25 | 2.4% | — | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | 9.4% | — | ||
| Q3 24 | 2.2% | — | ||
| Q2 24 | 2.9% | — | ||
| Q1 24 | 4.1% | — |
现金转化率GHRGLD
| Q4 25 | — | 2.58× | ||
| Q3 25 | — | 1.37× | ||
| Q2 25 | — | 1.15× | ||
| Q1 25 | — | 1.20× | ||
| Q4 24 | — | 1.31× | ||
| Q3 24 | — | 1.42× | ||
| Q2 24 | — | 1.40× | ||
| Q1 24 | — | 2.93× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
RGLD
| Gold | $216.9M | 58% |
| Pueblo Viejo | $47.3M | 13% |
| Andacollo | $32.6M | 9% |
| Silver | $32.1M | 9% |
| Other | $27.2M | 7% |
| Copper | $13.7M | 4% |
| Cortez Legacy Zone | $5.4M | 1% |
